Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orano Med and Orbit partner for radionuclide therapies discovery
As per the agreement terms, Orbit will discover peptide leads specific to targets related to certain tumours by deploying its bead-based peptide display engine. Orbit Discovery CEO Dr
As per the agreement terms, Orbit will discover peptide leads specific to targets related to certain tumours by deploying its bead-based peptide display engine. Orbit Discovery CEO Dr
An engineered interleukin-2 (IL-2)-diphtheria toxin fusion protein, Lymphir is intended for relapsed or refractory CTCL patients following treatment with a minimum of one systemic therapy previously. As per
As per the agreement, Procaps will be responsible for activities related to registration, branding, marketing along with commercialisation throughout Latin America. Procaps submitted an initial set of eight
Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,
The latest move comes after signing an exclusive licence agreement with HK inno.N in November 2020. The agreement granted sublicensing rights to UITC for developing, marketing, and manufacturing
The latest move is aimed at sharing the government’s objective to make obesity care accessible to patients with high unmet medical need. Through a controlled and limited launch,
The company will utilise proceeds from the round for further developing its technology platform to accelerate its lead programmes to clinical stage. The participants in the financing round
The approval was granted to the company’s Specialty Generics segment, operating as SpecGx. Mallinckrodt started selling the product after securing approval, which happened the day after the expiration
A small molecular compound and a novel type of calcimimetics discovered by Mitsubishi Tanabe Pharma Corporation, Orkedia Tablets suppresses parathyroid hormone (PTH) secretion as it acts on the
The designation will provide certain benefits to Faron including exemption of FDA application fees, tax credits for qualified trials, and on receiving regulatory approval, will get market exclusivity.